Serum Uric Acid and Risk of Cancer Mortality in a Large Prospective Male Cohort
Overview
Public Health
Authors
Affiliations
Objective: To examine the prognostic role of serum uric acid (SUA) for cancer mortality in apparently healthy men across a wide age range.
Methods: Prospective data from a large cohort of 83,683 male Austrian adults with a median follow-up of 13.6 years was analyzed. Cox proportional hazards models, adjusted for established risk factors, were calculated to evaluate SUA as a predictive marker for fatal cancer events.
Results: High SUA (>6.71 mg/dl) was independently associated with increased risk of mortality from all cancers, showing a clear dose-response relationship (p for trend < 0.0001); the adjusted hazard ratio for the highest versus lowest quintile of SUA was 1.41 (1.22-1.62). In subgroup analyses this hazard ratio increased to 1.53 (1.29-1.80) for participants aged <65 years. When considering the time interval between baseline SUA measurement and subsequent death, SUA levels were more predictive for "late deaths", occurring 10 or more years after screening (HR 1.65 [1.35-2.03], p < 0.0001), in comparison to deaths within 10 years after SUA measurement. In cancer site-specific analyses, SUA was significantly associated with deaths from malignant neoplasms of digestive organs (p = 0.03) and respiratory system and intrathoracic organs (p < 0.0001). Elevated SUA was further independently related to an increased risk of all-cause mortality (p < 0.0001).
Conclusions: Our results are contrary to the proposed antioxidant, inhibitory effect of SUA against cancer and rather suggest high SUA to be a valuable long-term surrogate parameter, indicative for a life-style at increased risk for the development of cancer.
Association between gout and cancers: A systematic review and meta-analysis.
Tian L, Wang Y, Zhang Y, Tian L, Wang H Medicine (Baltimore). 2024; 103(43):e40234.
PMID: 39470515 PMC: 11521056. DOI: 10.1097/MD.0000000000040234.
Kim S, Park I, Byun C, Choi H, Kwon M, Kim J J Clin Med. 2024; 13(11).
PMID: 38892847 PMC: 11173149. DOI: 10.3390/jcm13113136.
The potential of aryl hydrocarbon receptor as receptors for metabolic changes in tumors.
Wang Z, Zhang Y, Liao Z, Huang M, Shui X Front Oncol. 2024; 14:1328606.
PMID: 38434684 PMC: 10904539. DOI: 10.3389/fonc.2024.1328606.
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer.
Ivanina Foureau A, Sha W, Foureau D, Symanowski J, Farhangfar C, Mileham K Transl Lung Cancer Res. 2023; 11(12):2464-2476.
PMID: 36636422 PMC: 9830272. DOI: 10.21037/tlcr-22-377.
Anitha G, Kumar K, Deshpande G, Nagaraj M, Kalyani V J Oral Maxillofac Pathol. 2022; 26(2):218-227.
PMID: 35968187 PMC: 9364637. DOI: 10.4103/jomfp.jomfp_26_22.